UBM Tech today unveiled the new community-driven Bank Systems & Technology (banktech.com), an interactive platform for bank technology professionals to connect with peers, editors and industry experts. The redesigned site provides the latest news, commentary, and discussion on the most pressing issues that technology and business leaders face in the financial services market. More than 50 new community contributors involved in banking channel strategies, payments, security, bank core systems, data management and compliance trends will enrich its award-winning editorial coverage.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7233651-ubm-tech-unveils-new-community-driven-bank-systems-and-technology
Avigna Clinical Research Institute is modeled on the lines of some of the premier Clinical Research Institutes of India. We are dedicated and committed to provide excellent Clinical Research Professionals to the Clinical Research Industries.
UBM Tech today introduced the new community-driven Insurance & Technology (insurancetech.com), an interactive platform for insurance technology professionals to connect with peers, editors and industry experts. The redesigned site provides the latest news, commentary and discussion on the most pressing issues that technology and business leaders face in the insurance marketplace. Complementing the brand’s award-winning editorial is perspective from more than 50 community contributors and subject matter experts involved in channel strategies, security, data management, compliance, policy administration, claims and underwriting.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7302151-ubm-tech-introduces-the-new-insurance-and-technology-interactive-platform/
With gout incidence on the rise, an increasing number of medical professionals, across multiple fields of practice, will continue to be exposed to patients who suffer from gout and are seeking an accurate diagnosis and treatment. However, despite the availability of the “Guidelines for the Management of Gout” by the American College of Rheumatology (ACR), there are many inconsistencies in how gout is diagnosed, treated and discussed by medical professionals. Conflicting messages and treatment recommendations can contribute to confusion, and even lack of compliance, on behalf of the patient – particularly when gout is connected with comorbid conditions, such as kidney disease, heart disease or diabetes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7362551-gout-uric-acid-education-society-guaes-roundtable-consensus-paper/
OTC Markets Group Inc. (OTCQX: OTCM) and PR Newswire welcomed investor relations professionals from some of Europe’s largest corporations to the Westminster Hotel in central Paris on 21st January to take part in a breakfast forum aimed at educating European global companies about the OTCQX® and OTCQB® marketplaces in the US and providing guidance and best practices on cost-effectively reaching US investors.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7425751-otc-markets-us-investor-strategies/
The first Meet the Media of 2015 was hosted at One Great George Street, the home of the Institute of Civil Engineers, and featured Simon Jack giving an insight into the workings of the Today programme.
Simon has worked across every outlet at the BBC, presenting business news on the one o'clock, six o'clock and ten o’clock news and as the face of BBC Breakfast’s business news. He is currently the Business and Economics Presenter on Radio 4's Today Programme.
The reach of the programme dwarfs that of national newspapers with an audience of 7 million. Simon hosts the business slot at 6.15am which is listened to by an audience of almost exclusively ABC1 professionals. Simon explained to the PR and communications professionals attending the event that this is the opportunity to “talk about issues that affect you and your clients”.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7447651-meet-media-simon-jack/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Strategic Partners, Inc., the leader in the manufacturing and marketing of medical apparel, lab wear, footwear and accessories, today announced the launch of its next generation of medical apparel: scrubs, lab wear and accessories protected with CERTAINTY™ antimicrobial technology.
On a daily basis, many healthcare professionals are exposed to unwanted bacteria on their clothing. CERTAINTY antimicrobial technology can provide more fabric protection than traditional scrubs, giving healthcare professionals the freedom to perform their duties in comfortable, fashion-inspired clothing.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7458151-strategic-partners-certainty/
